Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc is well-positioned for positive stock performance due to anticipated accelerated growth in the spine market and strong sales in its Enabling Technologies segment, which should contribute to favorable margins. Recent performance metrics reveal a robust 10% growth in Nevro sales, primarily driven by solid U.S. spine performance, suggesting significant market traction that may enhance future revenue streams. Additionally, the company's focus on integrating NuVasive and improving manufacturing efficiency is expected to bolster its EBITDA margins to stabilize between 34-35% by 2026, providing a strong foundation for sustainable organic growth and improved free cash flow.

Bears say

Globus Medical faces a negative outlook primarily due to several identified risks, including slower-than-anticipated growth in the spine market and potential revenue disruptions stemming from recent mergers involving NuVasive and Nevro. Additionally, the company's bear case scenario hinges on a significant deceleration in revenue growth to the low-single digits and challenges related to the execution of new product launches and market expansion, which could hinder expected contributions from musculoskeletal products. Furthermore, potential declines in operating margins coupled with a stagnant capital environment for robotic purchasing could exacerbate the company's financial challenges.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.